$920,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Clinical Trial Data Requirements in AG Appropriations Bill; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient Experience/Patient Focused Drug Development within the FDA/AG Appropriations; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues. 340B; Medicare Negotiation, and Most Favored Nation. COINS Act Implementation; HR 9102 BINSA Bill; Supply Chain Issues; and Importation issues. Supply Chain issues; TRIP Waivers; and Vaccine Injury Compensation Program. S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property. Insulin; Pharmacy Benefits Managers (PBMs); Taxes- General Issues; China issues; Type 1 Diabetes Screening; and Vaccines - General Issues"
You can find more data on corporate lobbying on Quiver Quantitative.
SNY Hedge Fund Activity
We have seen 334 institutional investors add shares of SNY stock to their portfolio, and 320 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX removed 26,987,967 shares (-47.8%) from their portfolio in Q1 2026, for an estimated $1,300,280,250
- MORGAN STANLEY added 3,409,671 shares (+37.5%) to their portfolio in Q1 2026, for an estimated $164,277,948
- MILLENNIUM MANAGEMENT LLC added 3,303,600 shares (+2410.4%) to their portfolio in Q1 2026, for an estimated $159,167,448
- WELLINGTON MANAGEMENT GROUP LLP removed 2,928,047 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $141,073,304
- NATIXIS ADVISORS, LLC removed 2,368,138 shares (-73.2%) from their portfolio in Q1 2026, for an estimated $114,096,888
- ALYESKA INVESTMENT GROUP, L.P. added 2,306,229 shares (+inf%) to their portfolio in Q1 2026, for an estimated $111,114,113
- BLACKROCK, INC. removed 2,162,018 shares (-40.4%) from their portfolio in Q1 2026, for an estimated $104,166,027
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
